Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation
type: MedicalStudy
description: Efficacy and Safety of Bevacizumab Combined With Double Doses of Icotinib in Advanced Non-squamous Non-small Cell Lung Cancer With EGFR Exon 21 L858R Mutation: a Prospective, Single-arm, Phase 2 Clinical Trial
status: COMPLETED
study design: INTERVENTIONAL
phase: PHASE2
start date: 2022-01-30
end date: 2023-12-30
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT05263947
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: Tianjin Medical University Cancer Institute and Hospital
study subject: Carcinoma, Non-Small-Cell Lung
study subject: Bevacizumab
study subject: Tyrosine Kinase Inhibitor
study subject: EGFR L858R
keywords: PHASE2
keywords: INTERVENTIONAL
keywords: COMPLETED
keywords: Carcinoma, Non-Small-Cell Lung
keywords: Bevacizumab
keywords: Tyrosine Kinase Inhibitor
keywords: EGFR L858R

AI Analytics
type: Organization